CytomX Therapeutics, Inc. (NASDAQ:CTMX) Director Frederick W. Gluck sold 10,000 shares of CytomX Therapeutics stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $25.01, for a total value of $250,100.00. The transaction was disclosed in a filing with the SEC, which is available at this link.

Shares of CytomX Therapeutics, Inc. (CTMX) traded down $0.53 during trading hours on Monday, hitting $24.34. The stock had a trading volume of 634,516 shares, compared to its average volume of 404,293. CytomX Therapeutics, Inc. has a 12 month low of $10.64 and a 12 month high of $25.21. The company has a market capitalization of $934.87 and a PE ratio of -15.50.

Large investors have recently modified their holdings of the company. Macquarie Group Ltd. bought a new stake in shares of CytomX Therapeutics during the third quarter worth approximately $107,000. Legal & General Group Plc boosted its holdings in shares of CytomX Therapeutics by 28.6% during the second quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 1,434 shares during the period. Cubist Systematic Strategies LLC bought a new stake in shares of CytomX Therapeutics during the second quarter worth approximately $174,000. Voya Investment Management LLC bought a new stake in shares of CytomX Therapeutics during the second quarter worth approximately $203,000. Finally, Nationwide Fund Advisors boosted its holdings in shares of CytomX Therapeutics by 39.4% during the second quarter. Nationwide Fund Advisors now owns 16,365 shares of the biotechnology company’s stock worth $254,000 after acquiring an additional 4,622 shares during the period. Institutional investors own 63.13% of the company’s stock.

A number of research firms recently commented on CTMX. Wedbush set a $37.00 price target on CytomX Therapeutics and gave the stock a “buy” rating in a report on Wednesday, October 4th. Zacks Investment Research cut CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Oppenheimer restated a “hold” rating on shares of CytomX Therapeutics in a report on Wednesday, October 4th. Bank of America boosted their price objective on CytomX Therapeutics from $30.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, October 4th. Finally, Citigroup assumed coverage on CytomX Therapeutics in a report on Friday. They set a “buy” rating and a $40.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the company. CytomX Therapeutics currently has an average rating of “Buy” and an average price target of $32.78.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.watchlistnews.com/cytomx-therapeutics-inc-ctmx-director-sells-250100-00-in-stock/1798856.html.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.